2022 Alzheimer's disease facts and figures

DOI: https://doi.org/10.1002/alz.12638

2022-03-14

Abstract:Alzheimer's & Dementia, EarlyView.

clinical neurology

What problem does this paper attempt to address?

2023 Alzheimer's disease facts and figures

DOI: https://doi.org/10.1002/alz.13016

2023-03-16

Abstract:This article describes the public health impact of Alzheimer's disease, including prevalence and incidence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society. The Special Report examines the patient journey from awareness of cognitive changes to potential treatment with drugs that change the underlying biology of Alzheimer's. An estimated 6.7 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060 barring the development of medical breakthroughs to prevent, slow or cure AD. Official death certificates recorded 121,499 deaths from AD in 2019, and Alzheimer's disease was officially listed as the sixth‐leading cause of death in the United States. In 2020 and 2021, when COVID‐19 entered the ranks of the top ten causes of death, Alzheimer's was the seventh‐leading cause of death. Alzheimer's remains the fifth‐leading cause of death among Americans age 65 and older. Between 2000 and 2019, deaths from stroke, heart disease and HIV decreased, whereas reported deaths from AD increased more than 145%. This trajectory of deaths from AD was likely exacerbated by the COVID‐19 pandemic in 2020 and 2021. More than 11 million family members and other unpaid caregivers provided an estimated 18 billion hours of care to people with Alzheimer's or other dementias in 2022. These figures reflect a decline in the number of caregivers compared with a decade earlier, as well as an increase in the amount of care provided by each remaining caregiver. Unpaid dementia caregiving was valued at ‐ ‐ ‐ ‐ 345 billion. The Special Report examines whether there will be sufficient numbers of physician specialists to provide Alzheimer's care and treatment now that two drugs are available that change the underlying biology of Alzheimer's disease.

clinical neurology
2023 China Alzheimer’s Disease: Facts and Figures

Jinwen Xiao,Jianping Li,Jintao Wang,Xingyu Zhang,Cong Wang,Guoping Peng,Hua Hu,Huayan Liu,Jun Liu,Lu Shen,Nan Zhang,Ning Yan,Qinying Ma,Wanzhong Xu,Zhengluan Liao,Rujing Ren,Mingwei Wang,Enyan Yu,Jinzhou Tian,Huali Wang,Yong’an Sun,Hengge Xie,Gang Wang

DOI: https://doi.org/10.37819/hb.3.1771

2023-01-01

Abstract:In China, the aging population and the increasing incidence of Alzheimer's disease (AD) and other dementias have emerged as major medical concerns. Extensive research and new technologies on AD have provided possibilities for early intervention, including emerging biomarkers for detection and new drugs with disease-modifying therapy. This report includes a large amount of facts and figures to describe the understanding of patients and their families about the disease, discuss the problems they encounter in the current medical environment, and outline potential difficulties in clinical diagnosis and treatment status. Furthermore, people’s concerns, the overall effect on caregivers, and the development of AD treatment are presented in this report. Overall, to increase public awareness of the disease, this report suggests early detection, screening, and intervention for AD while calling on all sectors to work together to help AD patients.
2019 Alzheimer's disease facts and figures

DOI: https://doi.org/10.1016/j.jalz.2019.01.010

2019-03-01

Abstract:This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on caregivers and society. The Special Report examines the use of brief cognitive assessments by primary care physicians as a tool for improving early detection of dementia. An estimated 5.8 million Americans have Alzheimer's dementia. By mid-century, the number of people living with Alzheimer's dementia in the United States may grow to 13.8 million, fueled in large part by the aging baby boom generation. In 2017, official death certificates recorded 121,404 deaths from AD, making AD the sixth leading cause of death in the United States and the fifth leading cause of death among Americans age ≥65 years. Between 2000 and 2017, deaths resulting from stroke, heart disease, and prostate cancer decreased, whereas reported deaths from AD increased 145%. In 2018, more than 16 million family members and other unpaid caregivers provided an estimated 18.5 billion hours of care to people with Alzheimer's or other dementias. This care is valued at nearly $234 billion, but its costs extend to family caregivers' increased risk for emotional distress and negative mental and physical health outcomes. Average per-person Medicare payments for services to beneficiaries age ≥65 years with Alzheimer's or other dementias are more than three times as great as payments for beneficiaries without these conditions. Total payments in 2019 for health care, long-term care and hospice services for people age ≥65 years with dementia are estimated to be $290 billion. Early detection of Alzheimer's offers numerous medical, emotional and financial benefits—benefits that accrue to affected individuals and their families as well as to society at large. Alzheimer's Association surveys regarding brief cognitive assessments for detection of dementia found that while a large majority of seniors and primary care physicians say the assessments are important, only half of seniors have received an assessment, and only 16 percent of seniors receive regular cognitive assessments. Many educational opportunities exist to facilitate increased use of brief cognitive assessments in the primary care setting.
2020 Alzheimer's disease facts and figures

DOI: https://doi.org/10.1002/alz.12068

2020-03-01

Abstract:This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on caregivers and society. The Special Report discusses the future challenges of meeting care demands for the growing number of people living with Alzheimer's dementia in the United States with a particular emphasis on primary care. By mid-century, the number of Americans age 65 and older with Alzheimer's dementia may grow to 13.8 million. This represents a steep increase from the estimated 5.8 million Americans age 65 and older who have Alzheimer's dementia today. Official death certificates recorded 122,019 deaths from AD in 2018, the latest year for which data are available, making Alzheimer's the sixth leading cause of death in the United States and the fifth leading cause of death among Americans age 65 and older. Between 2000 and 2018, deaths resulting from stroke, HIV and heart disease decreased, whereas reported deaths from Alzheimer's increased 146.2%. In 2019, more than 16 million family members and other unpaid caregivers provided an estimated 18.6 billion hours of care to people with Alzheimer's or other dementias. This care is valued at nearly $244 billion, but its costs extend to family caregivers' increased risk for emotional distress and negative mental and physical health outcomes. Average per-person Medicare payments for services to beneficiaries age 65 and older with AD or other dementias are more than three times as great as payments for beneficiaries without these conditions, and Medicaid payments are more than 23 times as great. Total payments in 2020 for health care, long-term care and hospice services for people age 65 and older with dementia are estimated to be $305 billion. As the population of Americans living with Alzheimer's dementia increases, the burden of caring for that population also increases. These challenges are exacerbated by a shortage of dementia care specialists, which places an increasing burden on primary care physicians (PCPs) to provide care for people living with dementia. Many PCPs feel underprepared and inadequately trained to handle dementia care responsibilities effectively. This report includes recommendations for maximizing quality care in the face of the shortage of specialists and training challenges in primary care.
Dementia Research in 2022: Advancing Steadily on Reflection

Ya-Ru Zhang,Kevin Kuo,Qiang Dong,Jin-Tai Yu

DOI: https://doi.org/10.1016/s1474-4422(22)00473-2

IF: 59.935

2022-01-01

The Lancet Neurology

Abstract:In 2022, multiple research milestones have occurred in the field of dementia. Therapeutics went through a fundamental transition, with amyloid-β (Aβ) targeted drugs gradually moving from clinical trials into real-world application. Encouraging findings on biomarkers and risk factors also marked the ongoing shift towards precise diagnosis and early prevention. We believe that this progress has been achieved by given consideration to previously established notions.
2021 Alzheimer's disease facts and figures

DOI: https://doi.org/10.1002/alz.12328

2021-03-01

Abstract:This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on caregivers and society. The Special Report discusses the challenges of providing equitable health care for people with dementia in the United States. An estimated 6.2 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060 barring the development of medical breakthroughs to prevent, slow or cure AD. Official death certificates recorded 121,499 deaths from AD in 2019, the latest year for which data are available, making Alzheimer's the sixth-leading cause of death in the United States and the fifth-leading cause of death among Americans age 65 and older. Between 2000 and 2019, deaths from stroke, heart disease and HIV decreased, whereas reported deaths from AD increased more than 145%. This trajectory of deaths from AD was likely exacerbated in 2020 by the COVID-19 pandemic. More than 11 million family members and other unpaid caregivers provided an estimated 15.3 billion hours of care to people with Alzheimer's or other dementias in 2020. These figures reflect a decline in the number of caregivers compared with a decade earlier, as well as an increase in the amount of care provided by each remaining caregiver. Unpaid dementia caregiving was valued at $256.7 billion in 2020. Its costs, however, extend to family caregivers' increased risk for emotional distress and negative mental and physical health outcomes - costs that have been aggravated by COVID-19. Average per-person Medicare payments for services to beneficiaries age 65 and older with AD or other dementias are more than three times as great as payments for beneficiaries without these conditions, and Medicaid payments are more than 23 times as great. Total payments in 2021 for health care, long-term care and hospice services for people age 65 and older with dementia are estimated to be $355 billion. Despite years of efforts to make health care more equitable in the United States, racial and ethnic disparities remain - both in terms of health disparities, which involve differences in the burden of illness, and health care disparities, which involve differences in the ability to use health care services. Blacks, Hispanics, Asian Americans and Native Americans continue to have a higher burden of illness and lower access to health care compared with Whites. Such disparities, which have become more apparent during COVID-19, extend to dementia care. Surveys commissioned by the Alzheimer's Association recently shed new light on the role of discrimination in dementia care, the varying levels of trust between racial and ethnic groups in medical research, and the differences between groups in their levels of concern about and awareness of Alzheimer's disease. These findings emphasize the need to increase racial and ethnic diversity in both the dementia care workforce and in Alzheimer's clinical trials.
Estimating prevalence of early symptomatic Alzheimer's disease in the United States

Drew Spargo,Richard Zur,Pei‐Jung Lin,Patricia Synnott,Eric Klein,Ann Hartry

DOI: https://doi.org/10.1002/dad2.12497

2023-11-29

Abstract:Alzheimer's &Dementia: Diagnosis, Assessment &Disease Monitoring, Volume 15, Issue 4, October‐December 2023.
Alzheimer's disease drug development pipeline: 2022

Jeffrey Cummings,Garam Lee,Pouyan Nahed,Mina Esmail Zadeh Nojoo Kambar,Kate Zhong,Jorge Fonseca,Kazem Taghva

DOI: https://doi.org/10.1002/trc2.12295

2022-05-06

Abstract:Alzheimer's & Dementia: Translational Research & Clinical Interventions, Volume 8, Issue 1, 2022.
2024 Alzheimer's disease facts and figures

DOI: https://doi.org/10.1002/alz.13809

Abstract:This article describes the public health impact of Alzheimer's disease (AD), including prevalence and incidence, mortality and morbidity, use and costs of care and the ramifications of AD for family caregivers, the dementia workforce and society. The Special Report discusses the larger health care system for older adults with cognitive issues, focusing on the role of caregivers and non-physician health care professionals. An estimated 6.9 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060, barring the development of medical breakthroughs to prevent or cure AD. Official AD death certificates recorded 119,399 deaths from AD in 2021. In 2020 and 2021, when COVID-19 entered the ranks of the top ten causes of death, Alzheimer's was the seventh-leading cause of death in the United States. Official counts for more recent years are still being compiled. Alzheimer's remains the fifth-leading cause of death among Americans age 65 and older. Between 2000 and 2021, deaths from stroke, heart disease and HIV decreased, whereas reported deaths from AD increased more than 140%. More than 11 million family members and other unpaid caregivers provided an estimated 18.4 billion hours of care to people with Alzheimer's or other dementias in 2023. These figures reflect a decline in the number of caregivers compared with a decade earlier, as well as an increase in the amount of care provided by each remaining caregiver. Unpaid dementia caregiving was valued at $346.6 billion in 2023. Its costs, however, extend to unpaid caregivers' increased risk for emotional distress and negative mental and physical health outcomes. Members of the paid health care and broader community-based workforce are involved in diagnosing, treating and caring for people with dementia. However, the United States faces growing shortages across different segments of the dementia care workforce due to a combination of factors, including the absolute increase in the number of people living with dementia. Therefore, targeted programs and care delivery models will be needed to attract, better train and effectively deploy health care and community-based workers to provide dementia care. Average per-person Medicare payments for services to beneficiaries age 65 and older with AD or other dementias are almost three times as great as payments for beneficiaries without these conditions, and Medicaid payments are more than 22 times as great. Total payments in 2024 for health care, long-term care and hospice services for people age 65 and older with dementia are estimated to be $360 billion. The Special Report investigates how caregivers of older adults with cognitive issues interact with the health care system and examines the role non-physician health care professionals play in facilitating clinical care and access to community-based services and supports. It includes surveys of caregivers and health care workers, focusing on their experiences, challenges, awareness and perceptions of dementia care navigation.
Alzheimer's disease drug development pipeline: 2023

Jeffrey Cummings,Yadi Zhou,Garam Lee,Kate Zhong,Jorge Fonseca,Feixiong Cheng

DOI: https://doi.org/10.1002/trc2.12385

2023-05-26

ALZHEIMER'S & DEMENTIA: TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS

Abstract:Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 9, Issue 2, April‐June 2023.
Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021

A.P. Porsteinsson,R.S. Isaacson,S. Knox,M.N. Sabbagh,I. Rubino

DOI: https://doi.org/10.14283/jpad.2021.23

2021-01-01

Abstract:Alzheimer’s disease is a progressive, irreversible neurodegenerative disease impacting cognition, function, and behavior. Alzheimer’s disease progresses along a continuum from preclinical disease, to mild cognitive and/or behavioral impairment and then Alzheimer’s disease dementia. Recently, clinicians have been encouraged to diagnose Alzheimer’s earlier, before patients have progressed to Alzheimer’s disease dementia. The early and accurate detection of Alzheimer’s disease-associated symptoms and underlying disease pathology by clinicians is fundamental for the screening, diagnosis, and subsequent management of Alzheimer’s disease patients. It also enables patients and their caregivers to plan for the future and make appropriate lifestyle changes that could help maintain their quality of life for longer. Unfortunately, detecting early-stage Alzheimer’s disease in clinical practice can be challenging and is hindered by several barriers including constraints on clinicians’ time, difficulty accurately diagnosing Alzheimer’s pathology, and that patients and healthcare providers often dismiss symptoms as part of the normal aging process. As the prevalence of this disease continues to grow, the current model for Alzheimer’s disease diagnosis and patient management will need to evolve to integrate care across clinical disciplines and the disease continuum, beginning with primary care. This review summarizes the importance of establishing an early diagnosis of Alzheimer’s disease, related practical ‘how-to’ guidance and considerations, and tools that can be used by healthcare providers throughout the diagnostic journey.
Global trends in COVID-19 Alzheimer's related research: a bibliometric analysis

Chenjun Cao,Sixin Li,Gaoya Zhou,Caijuan Xu,Xi Chen,Huiwen Qiu,Xinyu Li,Ying Liu,Hui Cao,Changlong Bi

DOI: https://doi.org/10.3389/fneur.2023.1193768

IF: 3.4

2023-06-05

Frontiers in Neurology

Abstract:Background: The COVID-19 pandemic has significantly impacted public health, putting people with Alzheimer's disease at significant risk. This study used bibliometric analysis method to conduct in-depth research on the relationship between COVID-19 and Alzheimer's disease, as well as to predict its development trends. Methods: The Web of Science Core Collection was searched for relevant literature on Alzheimer's and Coronavirus-19 during 2019–2023. We used a search query string in our advanced search. Using Microsoft Excel 2021 and VOSviewer software, a statistical analysis of primary high-yield authors, research institutions, countries, and journals was performed. Knowledge networks, collaboration maps, hotspots, and regional trends were analyzed using VOSviewer and CiteSpace. Results: During 2020–2023, 866 academic studies were published in international journals. United States, Italy, and the United Kingdom rank top three in the survey; in terms of productivity, the top three schools were Harvard Medical School, the University of Padua, and the University of Oxford; Bonanni, Laura, from Gabriele d'Annunzio University (Italy), Tedeschi, Gioacchino from the University of Campania Luigi Vanvitelli (Italy), Vanacore, Nicola from Natl Ctr Dis Prevent and Health Promot (Italy), Reddy, P. Hemachandra from Texas Tech University (USA), and El Haj, Mohamad from University of Nantes (France) were the authors who published the most articles; The Journal of Alzheimer's Disease is the journals with the most published articles; "COVID-19," "Alzheimer's disease," "neurodegenerative diseases," "cognitive impairment," "neuroinflammation," "quality of life," and "neurological complications" have been the focus of attention in the last 3 years. Conclusion: The disease caused by the COVID-19 virus infection related to Alzheimer's disease has attracted significant attention worldwide. The major hot topics in 2020 were: "Alzheimer' disease," COVID-19," risk factors," care," and "Parkinson's disease." During the 2 years 2021 and 2022, researchers were also interested in "neurodegenerative diseases," "cognitive impairment," and "quality of life," which require further investigation.

neurosciences,clinical neurology
Special Session Best of 2023: Care of the elderly

R. Perneczky

DOI: https://doi.org/10.1192/j.eurpsy.2024.33

2024-08-30

European Psychiatry

Abstract:In the field of Alzheimer's disease disease-modifying therapy, there has been a shift in diagnosis from the later dementia stages towards the earlier stages, with the potential for pre-symptomatic diagnosis. The development of truly 'disease-modifying' therapies that target the underlying mechanisms of Alzheimer's disease has reached late stages of human clinical trials. The primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimer's disease, and tau protein which, when hyperphosphorylated, results in the self-assembly of tangles of paired helical filaments also believed to be involved in the pathogenesis of Alzheimer's disease. Therapeutic strategies aimed at preventing Aβ formation, blocking its aggregation into plaques, lowering its soluble levels in the brain, and disassembling existing amyloid plaques are among the main strategies employed to slow the progression of AD. First anti-amyloid antibody treatments have proven effective in late-stage clinical trials and are now being approved for clinical use in some countries, initiating a new are of treatment. In terms of blood-based early diagnosis, the development of in vivo biomarkers has shifted the diagnosis of Alzheimer's disease from the later dementia stages of disease towards the earlier stages and has introduced the potential for pre-symptomatic diagnosis. Recent study shows promising results for blood tests that could be used to identify Alzheimer's changes in the brain before the onset of any symptoms, which could result in preventative treatments being used before any memory loss. This presentation will highlight the most exciting development of the past year in the Alzheimer's disease therapy and diagnosis arena. Disclosure of Interest None Declared

psychiatry
Expanding the scope of health disparities research in Alzheimer's disease and related dementias

Igor Akushevich,Julia Kravchenko,Arseniy Yashkin,P. Murali Doraiswamy,Carl V. Hill,Alzheimer's Disease and Related Dementia Health Disparities Collaborative Group

DOI: https://doi.org/10.1002/dad2.12415

2023-03-18

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring

Abstract:Alzheimer's &Dementia: Diagnosis, Assessment &Disease Monitoring, Volume 15, Issue 1, January‐March 2023.
The past, present and future of Alzheimer's disease – part 1: the past

Ricardo Nitrini

DOI: https://doi.org/10.1055/s-0043-1777722

2023-12-01

Arquivos de Neuro-Psiquiatria

Abstract:Abstract Background Alzheimer's disease (AD) was described in 1907, and since then it changed from a relatively rare condition to one of the most prevalent diseases. Objective To describe the evolution of the notions of dementias and AD, and to investigate the reasons for the increase in scientific interest in AD. Methods A historical analysis was carried out on knowledge about dementia, the site of mental activity, the relationships between brain diseases and mental activity, and on the advances in research about AD, since its discovery until the publication of the amyloid cascade hypothesis in 1992. A search was carried out in the National Library of Medicine (PubMed) for scientific articles that included the terms dementia or AD over 50 years, from 1972 to 2021. Results The scientific research on AD increased from 615 papers with the term AD in the first decade (1972-1981), to 100,028 papers in the last decade (2012-2021): an increase of 162.6 times whereas publications with the term dementia increased 28.6 times in the same period. In the 1960s and 1970s, a consensus was reached that AD is responsible for the majority of cases of dementia previously known as senile dementia. In the 1980s, beta-amyloid peptide was identified in the core of the senile plaque, hyperphosphorylated tau protein was found in neurofibrillary tangles, and a mutation was discovered in a hereditary form of AD. Conclusion The expansion of the concept of AD to include senile dementia, and the discoveries that occurred in the 1980s greatly expanded research in AD.

neurosciences,psychiatry
Current Alzheimer disease research highlights: evidence for novel risk factors

Willa D. Brenowitz,Yang Xiang,Claire T. McEvoy,Cui Yang,Kristine Yaffe,Wei-Dong Le,Yue Leng

DOI: https://doi.org/10.1097/cm9.0000000000001706

IF: 6.133

2021-09-09

Chinese Medical Journal

Abstract:ABSTRACT: Alzheimer disease (AD) is the most common type of dementia characterized by the progressive cognitive and social decline. Clinical drug targets have heavily focused on the amyloid hypothesis, with amyloid beta (Aβ), and tau proteins as key pathophysiologic markers of AD. However, no effective treatment has been developed so far, which prompts researchers to focus on other aspects of AD beyond Aβ, and tau proteins. Additionally, there is a mounting epidemiologic evidence that various environmental factors influence the development of dementia and that dementia etiology is likely heterogenous. In the past decades, new risk factors or potential etiologies have been widely studied. Here, we review several novel epidemiologic and clinical research developments that focus on sleep, hypoxia, diet, gut microbiota, and hearing impairment and their links to AD published in recent years. At the frontiers of AD research, these findings and updates could be worthy of further attention.

medicine, general & internal
Knowledge domains and emerging trends of Genome-wide association studies in Alzheimer’s disease: A bibliometric analysis and visualization study from 2002 to 2022

Fanjing Kong,Tianyu Wu,Jingyi Dai,Jie Cai,Zhenwei Zhai,Zhishan Zhu,Ying Xu,Tao Sun

DOI: https://doi.org/10.1371/journal.pone.0295008

IF: 3.7

2024-01-19

PLoS ONE

Abstract:Objectives Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive and behavioral function. Studies have shown that genetic factors are one of the main causes of AD risk. genome-wide association study (GWAS), as a novel and effective tool for studying the genetic risk of diseases, has attracted attention from researchers in recent years and a large number of studies have been conducted. This study aims to summarize the literature on GWAS in AD by bibliometric methods, analyze the current status, research hotspots and future trends in this field. Methods We retrieved articles on GWAS in AD published between 2002 and 2022 from Web of Science. CiteSpace and VOSviewer software were applied to analyze the articles for the number of articles published, countries/regions and institutions of publication, authors and cited authors, highly cited literature, and research hotspots. Results We retrieved a total of 2,751 articles. The United States had the highest number of publications in this field, and Columbia University was the institution with the most published articles. The identification of AD-related susceptibility genes and their effects on AD is one of the current research hotspots. Numerous risk genes have been identified, among which APOE , CLU , CD2AP , CD33 , EPHA1 , PICALM , CR1 , ABCA7 and TREM2 are the current genes of interest. In addition, risk prediction for AD and research on other related diseases are also popular research directions in this field. Conclusion This study conducted a comprehensive analysis of GWAS in AD and identified the current research hotspots and research trends. In addition, we also pointed out the shortcomings of current research and suggested future research directions. This study can provide researchers with information about the knowledge structure and emerging trends in the field of GWAS in AD and provide guidance for future research.

multidisciplinary sciences
Epidemiological Insights, Risk Factors and Prevention Pathways

Israel Contador,Bárbara Buch-Vicente,Teodoro del del Ser,Sara Llamas-Velasco,Alberto Villarejo-Galende,Julián Benito-León,Félix Bermejo-Pareja

DOI: https://doi.org/10.3390/jcm13144100

IF: 3.9

2024-07-14

Journal of Clinical Medicine

Abstract:Alzheimer's disease (AD), the most common cause of dementia, is a complex and multifactorial condition without cure at present. The latest treatments, based on anti-amyloid monoclonal antibodies, have only a modest effect in reducing the progression of cognitive decline in AD, whereas the possibility of preventing AD has become a crucial area of research. In fact, recent studies have observed a decrease in dementia incidence in developed regions such as the US and Europe. However, these trends have not been mirrored in non-Western countries (Japan or China), and the contributing factors of this reduction remain unclear. The Lancet Commission has delineated a constrained classification of 12 risk factors across different life stages. Nevertheless, the scientific literature has pointed to over 200 factors—including sociodemographic, medical, psychological, and sociocultural conditions—related to the development of dementia/AD. This narrative review aims to synthesize the risk/protective factors of dementia/AD. Essentially, we found that risk/protective factors vary between individuals and populations, complicating the creation of a unified prevention strategy. Moreover, dementia/AD explanatory mechanisms involve a diverse array of genetic and environmental factors that interact from the early stages of life. In the future, studies across different population-based cohorts are essential to validate risk/protective factors of dementia. This evidence would help develop public health policies to decrease the incidence of dementia.

medicine, general & internal
The role of astrocytes in Alzheimer's disease: a bibliometric analysis

Xiaoqiong An,Jun He,Bin Bi,Gang Wu,Jianwei Xu,Wenfeng Yu,Zhenkui Ren

DOI: https://doi.org/10.3389/fnagi.2024.1481748

IF: 4.8

2024-11-28

Frontiers in Aging Neuroscience

Abstract:The final, formatted version of the article will be published soon. You have multiple emails registered with Frontiers: Please enter your email address: If you already have an account, please login You don't have a Frontiers account ? You can register here Background: Alzheimer's disease (AD) is a neurodegenerative disorder marked by cognitive decline and memory loss. Recent research underscores the crucial role of astrocytes in AD. This study reviews research trends and contributions on astrocytes in AD from 2000 to 2024, shedding light on the evolving research landscape. Methods: We conducted a bibliometric analysis using data from the Web of Science Core Collection, covering publications from January 1, 2000, to July 6, 2024, on "Alzheimer's disease" and "astrocytes." We identified 5,252 relevant English articles and reviews. For data visualization and analysis, we used VOSviewer, CiteSpace, and the R package "bibliometrix," examining collaboration networks, co-citation networks, keyword co-occurrence, and thematic evolution. Results: Between 2000 and 2024, 5,252 publications were identified, including 4,125 original research articles and 1,127 review articles. Publications increased significantly after 2016. The United States had the most contributions (1,468), followed by China (836). Major institutions were the University of California system (517) and Harvard University (402). The Journal of Alzheimer's Disease published the most articles (215). Verkhratsky A was the top author with 51 papers and 1,585 co-citations. Conclusion: Our extensive bibliometric analysis indicates a significant increase in research on astrocytes in AD over the past twenty years. This study emphasizes the growing acknowledgment of astrocytes' crucial role in AD pathogenesis and points to future research on their mechanisms and therapeutic potential.

neurosciences,geriatrics & gerontology,gerontology
FROM THE WHO RESEARCH PRIORITIES AND RESEARCH PORTFOLIO ANALYSIS TO THE IDENTIFICATION OF RESEARCH GAPS TO REDUCE THE GLOBAL BURDEN OF DEMENTIA

Hiral Shah,Emiliano Albanese,Cynthia Duggan,Igor Rudan,Kenneth M. Langa,Maria C. Carrillo,Kit Yee Chan,Yves Joanette,Martin Prince,Shekhar Saxena,Heather M. Snyder,Reisa A. Sperling,Mathew Varghese,Huali Wang,Marc Wortmann,Tarun Dua

DOI: https://doi.org/10.1016/j.jalz.2016.06.395

2016-01-01

Alzheimer s & Dementia

Abstract:This abstract is embargoed as part of the AAIC 2015 Featured News Program and will be released on Monday, July 25 after 8:00 AM. The full abstract content will be posted for your viewing after the embargo lifts. All abstracts will be published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

2022 Alzheimer's disease facts and figures

2023 Alzheimer's disease facts and figures

2023 China Alzheimer’s Disease: Facts and Figures

2019 Alzheimer's disease facts and figures

2020 Alzheimer's disease facts and figures

Dementia Research in 2022: Advancing Steadily on Reflection

2021 Alzheimer's disease facts and figures

Estimating prevalence of early symptomatic Alzheimer's disease in the United States

Alzheimer's disease drug development pipeline: 2022

2024 Alzheimer's disease facts and figures

Alzheimer's disease drug development pipeline: 2023

Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021

Global trends in COVID-19 Alzheimer's related research: a bibliometric analysis

Special Session Best of 2023: Care of the elderly

Expanding the scope of health disparities research in Alzheimer's disease and related dementias

The past, present and future of Alzheimer's disease – part 1: the past

Current Alzheimer disease research highlights: evidence for novel risk factors

Knowledge domains and emerging trends of Genome-wide association studies in Alzheimer’s disease: A bibliometric analysis and visualization study from 2002 to 2022

Epidemiological Insights, Risk Factors and Prevention Pathways

The role of astrocytes in Alzheimer's disease: a bibliometric analysis

FROM THE WHO RESEARCH PRIORITIES AND RESEARCH PORTFOLIO ANALYSIS TO THE IDENTIFICATION OF RESEARCH GAPS TO REDUCE THE GLOBAL BURDEN OF DEMENTIA